Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

individualized MVA-based vaccine TG4050

An off-the-shelf (OTS) individualized vaccine comprised of a modified Vaccinia virus Ankara (MVA) viral vector encoding tumor-specific neoantigens (TSNAs), with potential immunostimulatory and antineoplastic activities. Following administration of the individualized MVA-based vaccine TG4050, the neoantigens are expressed and presented to the immune system, which induces the activation of a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing the patient-specific neoantigens.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:MVA-neoantigen vaccine TG4050
neoantigen-expressing MVA-based vaccine TG4050
TG4050 vaccine
Code name:TG 4050
TG-4050
TG4050
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search